Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT(2A) and dopamine D(2) receptors, as well as a unique agonist effects on serotonin 5-HT(1A) receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.
Otsuka
Tatsui
T
Department of Psychiatry, Yokohama City University School of Medicine: 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Togo
Takashi
T
Sugiyama
Naoya
N
Uehara
Kumi
K
Yoshimi
Asuka
A
Karashima
Aya
A
Shioya
Hiromi
H
Hirayasu
Yoshio
Y
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D054833:Isoindoles; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000150:complications / Q000188:drug therapy*; D017374:Paroxetine / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D007211:Indoles; D054833:Isoindoles; D013844:Thiazoles; D017374:Paroxetine; C065533:perospirone